PharmaCyte Biotech Inc (PMCB)

[1234jklm]

The value of pmcb is that it’s a platform

With some pharma stocks you are buying a medication which has one use.

Our cell encapsulation technology is like visa to the internet.

There are hundreds of ways the internet can sell but they all need a way to pay.

There are hundreds of ways cells can be used to treat medicine

But if they are to be affordable and commercial they all need a way to function while avoiding the immune system and they need to be able to remain in place to be effective.

Pancreatic cancer s just the initial way we show the technology works in a peer reviewed, industry accepted way. That will change everything.

Jdrf will take s seriously as an encapsulation technology when we have peer reviewed data.

Funding will follow.

And partnerships.

Stem cell treatments are the future but they need to be encapsulated to be handled effectively and they need to remain in position for maximum benefit. And encapsulation makes their storage and production far easier. Cells are fragile. Cycaps protect them, make them freezable and make them widely commercial.

Thomas Yuen is not involved as a director because he wants the directors fees. Look at his history of taking next stage technology and making it immensely valuable.

What we have here is the delivery method for a major section of the next generation of medicine.

It’s taking time because The approval process take many years whether you’re a big or small pharma. It costs tens of millions.

By choosing one of the most difficult cancers and an unmet medical need the company has found a path to fastrack the technology. It’s really smart of them.

We know from the early trials that activating ifosfamide next to the tumor can make inoperable tumors operable. We know that it’s virtually side effect free. That’s with two doses only.

We know the technology is now vastly improved and our trial will give 12-18 doses and the results measured by imaging which is vastly better than 20 years ago.

Don’t lose sight of the value due to impatience.

One day soon the pr will land which says ind has been submitted.

We know how painstaking the preparations have been. They know they have one shot at this and want to get it perfect the first time. They are well informed and surrounded by an experienced and impressive team of doctors.

The trial has been designed by some of the world’s leading oncologists.

‘We’re there.”